HC Wainwright Predicts Inventiva FY2026 Earnings

Key Points

• HC Wainwright forecasts Inventiva will lose $0.59 per share in FY2026, versus the current consensus estimate of a $0.75 loss. It also projects narrowing losses through FY2030.
• The firm maintained a Buy rating and $14 price target. Analysts’ consensus is “Moderate Buy,” with an average target of $14.67.
• Inventiva reported a quarterly loss of $0.14 per share and $0.75 million in revenue. Its shares opened at $3.80, while institutional investors own 19.06% of the company.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Inventiva in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst A. Ghosh expects that the company will post earnings of ($0.59) per share for the year. HC Wainwright currently has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Inventiva's current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Inventiva's FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.46) EPS and FY2030 earnings at ($0.09) EPS.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million during the quarter.

Several other analysts also recently commented on the stock. Wall Street Zen upgraded shares of Inventiva from a "sell" rating to a "hold" rating in a report on Saturday, October 3rd. Truist Financial boosted their price objective on Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, October 2nd. Guggenheim upped their price objective on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, September 15th. Weiss Ratings raised Inventiva from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 23rd. Finally, Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Inventiva has a consensus rating of "Moderate Buy" and an average target price of $14.67.

Inventiva Price Performance

IVA opened at $3.80 on Monday. The firm's fifty day moving average price is $3.73 and its two-hundred day moving average price is $4.83. Inventiva has a 1 year low of $2.82 and a 1 year high of $7.29.

Institutional Investors Weigh In On Inventiva

Hedge funds have recently modified their holdings of the stock. Aberdeen Group plc boosted its holdings in shares of Inventiva by 36.3% in the third quarter. Aberdeen Group plc now owns 3,145,711 shares of the company's stock worth $11,608,000 after acquiring an additional 837,938 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Inventiva by 7.0% in the third quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company's stock valued at $332,000 after purchasing an additional 5,857 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company's stock valued at $142,000 after purchasing an additional 17,000 shares in the last quarter. Platt Investment Counsel LLC bought a new stake in shares of Inventiva during the 3rd quarter valued at $45,000. Finally, Engineers Gate Manager LP raised its stake in shares of Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after purchasing an additional 43,280 shares during the period. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.